Company intelligence / Profile preview
Vyluma
Bridgewater, New Jersey, United Statesvyluma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vyluma's lead compound NVK002 (low dose atropine 0.01%) completed Phase III CHAMP clinical study with positive results after four years of treatment and follow-up, showing continued strong safety, absence of rebound upon washout, and continued efficacy for treating myopia in children. FDA decision expected in January 2024.[5]
- Therapeutic areas
- Ophthalmology
- Modalities
- Pharmaceutical eye dropstopical treatments
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Zhaoke Ophthalmology (China and South East Asia)Laboratories Théa (Europe)
Beyond the preview
Go deeper on Vyluma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vyluma.